El-Badawy and El-Badri [42] conducted a meta-analysis of the therapeutic effects of different sources of stem cells in T1DM and T2DM by evaluating C-peptide, HbA1c, insulin requirements, and adverse effects, showing improved outcomes with stem cell therapy, especially CD34+ hematopoietic stem cell therapy. The gene discussed is CD34; the disease is type 1 diabetes mellitus.